Abstract: In recent years, targeted therapy with epidermal growth factor receptor (EGFR) has played an important role in the treatment of non-small cell lung cancer (NSCLC). However, primary and acquired drug resistance have limited its efficacy. Studies have shown that autophagy is one of the mechanisms of targeted drug resistance, and the combination of autophagy regulators is expected to solve the problem of drug resistance to targeted therapy for non-small cell lung cancer.